menu search

BBIO / BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why

BridgeBio Pharma (BBIO) Surges 77% YTD: Here's Why
Shares of BridgeBio (BBIO) are up rising since the company announced positive data from a mid-stage study, which evaluated its experimental drug infigratinib in children with achondroplasia, a form of dwarfism. Read More
Posted: Mar 22 2023, 14:29
Author Name: Zacks Investment Research
Views: 111251

BBIO News  

Why BridgeBio Pharma Was a Healthy Stock Today

By The Motley Fool
October 24, 2023

Why BridgeBio Pharma Was a Healthy Stock Today

A well-respected financial services company initiated coverage on the biotech. It flagged it with its equivalent of a buy recommendation. more_horizontal

BridgeBio: Bets Acoramidis As The Pfizer Spoiler

By Seeking Alpha
September 25, 2023

BridgeBio: Bets Acoramidis As The Pfizer Spoiler

BridgeBio Pharma's Q2 2023 YoY revenue plummeted, but PIPE financing extends cash runway to 15 months, alleviating short-term liquidity concerns. Acor more_horizontal

Andreas Halvorsen's Firm Ups Inhibrx Stake

By GuruFocus
September 1, 2023

Andreas Halvorsen's Firm Ups Inhibrx Stake

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stak more_horizontal

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

By GlobeNewsWire
August 24, 2023

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage more_horizontal

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?

By The Motley Fool
August 9, 2023

Wall Street Thinks BridgeBio Pharma Could Rise Over 40% -- But Will It?

This young biotech might soon commercialize a new medicine. Analysts see BridgeBio's shares headed upward. more_horizontal

Why Shares of BridgeBio Pharma Skyrocketed This Week

By The Motley Fool
July 21, 2023

Why Shares of BridgeBio Pharma Skyrocketed This Week

BridgeBio Pharma focuses on oncology and genetic diseases. The company said that acoramidis fared well in treating a heart muscle disease. more_horizontal

BridgeBio Pharma Surges on Positive Heart Drug News

By GuruFocus
July 18, 2023

BridgeBio Pharma Surges on Positive Heart Drug News

BridgeBio Pharma ( BBIO , Financial) is a clinical-stage biopharmaceutical company that focuses on developing transformative medicines for patients wi more_horizontal

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

By Zacks Investment Research
July 18, 2023

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate more_horizontal


Search within

Pages Search Results: